Primary central nervous system lymphomas in 72 immunocompetent patients: pathologic findings and clinical correlations. Groupe Ouest Est d'étude des Leucénies et Autres Maladies du Sang (GOELAMS)
We reviewed 72 primary central nervous system lymphomas occurring in immunocompetent patients. The cases were reviewed for clinical data, histology, immunophenotype, bcl-2 and p53 expression, and Epstein-Barr virus association. Follow-up was available for 40 patients included in the Groupe Ouest Est d'étude des Leucénies et Autres Maladies du Sang (GOELAMS) lymphomes cérébraux primitifs (LCP 88) trial. Each diagnosis, requiring a consensus among at least 3 pathologists, was performed according to the recent Revised European-American Lymphoma classification and equivalents in the updated Kiel classification. Tumors were predominantly classified as diffuse large B-cell lymphomas. There were 3 T-cell lymphomas and 1 Hodgkin lymphoma. The proteins bcl-2 and p53 were expressed in 35% and 16% of the tested cases, respectively. Epstein-Barr virus was not found by in situ hybridization except in the case classfied as a cerebral localization of Hodgkin disease. No significant association was found between subtypes, bcl-2 or p53 expression, and patient survival. From the standpoint of their biologic characteristics, primary central nervous system lymphomas are very similar to systemic diffuse large B-cell lymphomas. In contrast to AIDS-related primary central nervous system lymphomas, primary central nervous system lymphomas are rarely associated with Epstein-Barr virus and in immunocompetent patients they express bcl-2 at a relatively low rate.
Camilleri-Broët
S
S
Service de Neuropathologie, Groupe hospitalier Pitié-Salpêtrière, Paris, France.
Martin
A
A
Moreau
A
A
Angonin
R
R
Hénin
D
D
Gontier
M F
MF
Rousselet
M C
MC
Caulet-Maugendre
S
S
Cuillière
P
P
Lefrancq
T
T
Mokhtari
K
K
Morcos
M
M
Broët
P
P
Kujas
M
M
Hauw
J J
JJ
Desablens
B
B
Raphaël
M
M
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016543:Central Nervous System Neoplasms / Q000276:immunology / Q000382:microbiology / Q000473:pathology*; D005260:Female; D004854:Herpesvirus 4, Human / Q000235:genetics; D006689:Hodgkin Disease / Q000276:immunology / Q000473:pathology; D006801:Humans; D007121:Immunocompetence; D007150:Immunohistochemistry; D016130:Immunophenotyping; D017403:In Situ Hybridization; D008223:Lymphoma / Q000276:immunology / Q000382:microbiology / Q000473:pathology*; D016393:Lymphoma, B-Cell / Q000276:immunology / Q000473:pathology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000276:immunology / Q000473:pathology; D016399:Lymphoma, T-Cell / Q000276:immunology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000032:analysis; D012367:RNA, Viral / Q000032:analysis; D016159:Tumor Suppressor Protein p53 / Q000032:analysis
D019253:Proto-Oncogene Proteins c-bcl-2; D012367:RNA, Viral; D016159:Tumor Suppressor Protein p53